Ask AI
ProCE Banner Events

Share

Myeloma Myth Busters: Investigating the Now, Soon, and Future Clinical Implications of CELMoDs

Join us either in person or online for this engaging interactive symposium in conjunction with ASH 2025 with a novel gameshow format built on “two truths and a myth” in which a panel of experts will discuss the use of CELMoD therapy for multiple myeloma. 

Friday Satellite Symposium preceding the 67th ASH Annual Meeting and Exposition. 

Physicians ABIM MOC: maximum of 2.00 Medical Knowledge MOC points

Physicians: maximum of 2.00 AMA PRA Category 1 Credits™

Who Should Attend

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Time and location

Friday, December 05, 2025

3:00 PM - 5:30 PM Eastern Time (ET)

In-person

3:30 PM - 5:30 PM Eastern Time (ET)

Virtual

The Hyatt Regency Orlando
9801 International Dr
Orlando, Florida 32819

Regency OPQ

Agenda

Registration & Refreshments: 3:00 PM - 3:30 PM ET

Symposium: 3:30 PM - 5:30 PM ET

 

Round 1: The Why and How of CELMoDs for MM

Round 2: Emerging Data, Early Disease: CELMoDs in Maintenance and Early-Relapse Settings

Lightning Round: MRD—Trial Endpoint or Clinical Tool?

Round 3: The Now, Soon, and Future: Integrating CELMoD Therapy Into Treatment of MM

Final Panel Discussion With Q&A 

Location

Venue Name

The Hyatt Regency Orlando

Address

The Hyatt Regency Orlando
9801 International Dr
Orlando, Florida 32819

Room Name

Regency OPQ

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in management of patients with multiple myeloma.

Target Audience
This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate how differences in cereblon affinity and binding potency influence the antimyeloma activity of individual CELMoDs and IMiDs

  • Appraise emerging data for CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma

  • Assess the clinical implication and association of achieving MRD negativity on treatment as a surrogate marker of long-term outcomes

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials of CELMoD-based therapies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Clinical Care Options, LLC dba Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC dba Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Clinical Care Options, LLC

Supporter

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.